SCHEMBL17985484

SCHEMBL17985484

Cc1cc(N(C)C)nc(NC(=N)Nc2ccc(Cl)c(Cl)c2)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 2/20 0.47
HRH1 P35367 2/20 0.47
HTR2B P41595 2/20 0.47
MCHR1 Q99705 2/20 0.47
SLC2A1 P11166 1/20 0.46
TAAR1 Q96RJ0 1/20 0.46
APEX1 P27695 1/20 0.43
TGM2 P21980 1/20 0.42
KCNH2 Q12809 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MAPT P10636 3/20 0.39
ADRA1A P35348 1/20 0.39
ALDH1A1 P00352 2/20 0.38
POLB P06746 2/20 0.38
GBA1 P04062 1/20 0.38
LMNA P02545 2/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18037986 0.85 SLC2A1 (0.61) ADRA2AHRH1HTR2BMCHR1SLC2A1
SCHEMBL17985492 0.84 KMT2A (0.49) APEX1MEN1KMT2ANPC1RAB9A
SCHEMBL20799360 0.84 NPC1 (0.44) APEX1MEN1KMT2ANPC1RAB9A
SCHEMBL4103203 0.83 NPC1 (0.43) APEX1MEN1KMT2ANPC1RAB9A
SCHEMBL18019581 0.82 NPC1 (0.42) ADRA2AHTR2BAPEX1KCNH2MEN1
SCHEMBL17985643 0.79 DNM2 (0.46) MCHR1APEX1NPC1RAB9AMAPT
SCHEMBL5923656 0.79 NPC1 (0.45) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL17985674 0.77 STK17A (0.39) SLC2A1NPC1RAB9AMAPTALDH1A1
SCHEMBL25858218 0.77 SLC2A1 (0.60) ADRA2AHRH1HTR2BMCHR1SLC2A1
SCHEMBL17985700 0.76 LMNA (0.48) ADRA2AHRH1HTR2BMCHR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10227333-B2 Inhibition of OLIG2 activity Curtana Pharmaceuticals, Inc. (US) 2019-03-12 US disclosed
US-10227333-B2 Inhibition of OLIG2 activity Curtana Pharmaceuticals, Inc. (US) 2019-03-12 US disclosed
US-20160237069-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2016-08-18 US disclosed
US-20160237069-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2016-08-18 US disclosed
US-20160237069-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2016-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227333-B2 Inhibition of OLIG2 activity GLI2, ING2, GMFG ADRA2A 4026/4885HRH1 4429/4885HTR2B 3862/4885
US-20160237069-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG ADRA2A 4026/4885HRH1 4429/4885HTR2B 3862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.